U.S. Patent No. 8,140,322 B2 Labeling Translation Risk Management

Crimson Life Sciences

Founded in 1992, Crimson is the only translation practice devoted to Class II and III devices and Class B, C, and D IVDs. Thanks to our exclusive dedication to the medical device industry, we understand the important patient safety and risk management function of translated labeling. Built on over 20 years of experience, we also deliver fluent, technically accurate translations of device marketing and training materials.

Expert Opinion

$400 million potential savings for the device industry with advanced content management technology.